Awesome all round news...if I were to highlight the Ann, every line would be bright yellow!
One key standout for me is related to inflammation and wider applicability:”Incannex has expanded its provisional patent protection to cover the treatment of a range of other inflammatory diseases that represent broad potential market opportunities for the Company, which are currently being evaluated.”
Is in-human trials a pre-requisite for FDA EUA?
Ann: Positive IHL-675A in vivo results and FDA Pathway, page-18
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)